- Supported exchanges /
- KO /
- 102460.KO
Reyon Pharmaceutical Co Ltd (102460 KO) stock market data APIs
REYON Pharmaceutical Co., Ltd. manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides; angiotensin II receptor antagonists; antibiotics; anticholinergics; antiemetic; antihypertensives; anti-inflammatory enzymes; antilipidemic, antirheumatic, and oral hypoglycemic agents; anti-peptic ulcer; antispasmodics; benign prostatic hypertrophy; cough and cold remedies; cardiac stimulant; genitourinary smooth muscle relaxants; hemostatics; immunosuppressants; rheumatoid arthritis; local anesthetics; migraine drugs; miscellaneous cardiovascular system drugs; neuromuscular disorder related drugs; nootropics and neurotonics; NSAIDs; respiratory stimulants; skeletal muscle relaxants; and vasodilators. It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis; VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer; RY103 [NS101], therapeutics antibody for Alzheimer; and RY104, a gene therapy to treat age-related macular degeneration, as well as BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B; RY105, gene therapy to treat liver fibrosis; GB102, for treatment of chronic kidney and coronary artery disease; RY110 which is an iPSC-derived NK cell therapy for solid tumors; RY108, an antifungal drug which is under preclinical study. In addition, the company engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases; and RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. REYON Pharmaceutical Co., Ltd. was founded in 1955 and is headquartered in Seoul, South Korea.
Reyon Pharmaceutical Co Ltd Financial Data Overview
14650 | |
14400 | |
- | |
14780 | |
14400 | |
11170-18650 | |
268 512 M | |
18 341 K | |
148 991 M | |
33.768 | |
0.0105 | |
0.915 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Reyon Pharmaceutical Co Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 148 991 M
- EBITDA 6 196 M
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Reyon Pharmaceutical Co Ltd Earnings via APIs
- Latest Release 2024-09-30
- EPS/Forecast NaN
Get Reyon Pharmaceutical Co Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: